Evidence map›Paper›PMID 27399306›Full record

ArticlePLoS pathogens2016

Adapting SHIVs In Vivo Selects for Envelope-Mediated Interferon-α Resistance.

David F Boyd, Amit Sharma, Daryl Humes, Cecilia Cheng-Mayer, Julie Overbaugh

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Virus-Host Gene Interactions Define HIV-1 Disease Progression.Current topics in microbiology and immunology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

David F BoydDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Amit SharmaDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Daryl HumesDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Cecilia Cheng-MayerAaron Diamond Research Center, New York, New York, United States of America.
Julie OverbaughDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Fred Hutch Cancer Center · USAaron Diamond AIDS Research Center · USUniversity of Washington · US

Funding

EARLY INFECTION IN WOMEN EXPOSED MUCOSALLY TO HIV-1R37AI038518 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 1999 to 2019
$12.9M
TOWARDS A MORE RELEVANT MODEL OF HIV INFECTIONDP1DA039543 · NIDA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 2015 to 2019
$4.4M
Viral Pathogenesis Training ProgramT32AI083203 · NIAID · UNIVERSITY OF WASHINGTON · PI BLOOM, JESSE D, LAGUNOFF, MICHAEL · 2009 to 2023
$2.7M
Generation of Genotypically Diverse R5 SHIVs as Tools in HIV-1 Vaccine ResearchR24AI112350 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI CHENG-MAYER, CECILIA C · 2014 to 2015
$1.7M
Host innate immune response as a barrier to cross-species retrovirus transmissionR00AI125136 · NIAID · OHIO STATE UNIVERSITY · PI SHARMA, AMIT · 2019 to 2020
$498k
Host Innate Immune Response as a Barrier to Cross-Species Retrovirus TransmissionK99AI125136 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SHARMA, AMIT · 2016 to 2017
$194k
NIAID NIH HHS K99 AI125136NIAID NIH HHS R00 AI125136NIAID NIH HHS R24 AI112350NIAID NIH HHS R37 AI038518NIAID NIH HHS T32 AI083203NIDA NIH HHS DP1 DA039543
6 · The paper itself

Abstract

Lentiviruses are able to establish persistent infection in their respective hosts despite a potent type-I interferon (IFN-I) response following transmission. A number of IFN-I-induced host factors that are able to inhibit lentiviral replication in vitro have been identified, and these studies suggest a role for IFN-induced factors as barriers to cross-species transmission. However, the ability of these factors to inhibit viral replication in vivo has not been well characterized, nor have the viral determinants that contribute to evasion or antagonism of the host IFN-I response. In this study, we hypothesized that the host IFN-I response serves as a strong selective pressure in the context of SIV/HIV chimeric virus (SHIV) infection of macaques and sought to identify the viral determinants that contribute to IFN-I resistance. We assessed the ability of SHIVs encoding HIV-1 sequences adapted by serial passage in macaques versus SHIVs encoding HIV sequences isolated directly from infected individuals to replicate in the presence of IFNα in macaque lymphocytes. We demonstrate that passage in macaques selects for IFNα resistant viruses that have higher replication kinetics and increased envelope content. SHIVs that encode HIV-1 sequences derived directly from infected humans were sensitive to IFNα -induced inhibition whereas SHIVs obtained after passage in macaques were not. This evolutionary process was directly observed in viruses that were serially passaged during the first few months of infection-a time when the IFNα response is high. Differences in IFNα sensitivity mapped to HIV-1 envelope and were associated with increased envelope levels despite similar mRNA expression, suggesting a post-transcriptional mechanism. These studies highlight critical differences in IFNα sensitivity between HIV-1 sequences in infected people and those used in SHIV models.

Indexed as

AnimalsBlotting, WesternChimeraDisease Models, Animalenv Gene Products, Human Immunodeficiency VirusHIV-1HIV InfectionsInterferon-alphaMacacaPolymerase Chain ReactionSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency Virusenv Gene Products, Human Immunodeficiency VirusInterferon-alpha

Identifiers

PMID27399306
PMCPMC4939950
OpenAlexW2463634415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.